Jinxin Fertility Group Limited (abbreviated as JXR) disclosed that it bought back 3.52 million ordinary shares on 27 March 2026 via on-market transactions. The purchase price ranged between HKD 2.26 and HKD 2.31 per share, with a volume-weighted average of HKD 2.29, bringing the cash outflow for the day to HKD 8.05 million.

Including this tranche, JXR has repurchased 43.18 million shares since the current mandate was approved on 26 June 2025, equivalent to 1.57 % of the company’s issued share capital on the mandate date. The mandate authorises the repurchase of up to 274.47 million shares, leaving a remaining capacity of approximately 231.29 million shares.

Repurchased shares are being held for cancellation; none have yet been cancelled, leaving the company’s issued share capital unchanged at 2.74 billion shares (excluding 13.00 million treasury shares) as of 27 March 2026. Under Hong Kong listing rules, JXR is restricted from issuing new shares until 26 April 2026, 30 days after the latest buyback.